Background: There is still no consensus on screening, threshold levels and treatment of gestational diabetes mellitus. Furthermore, the importance of a positive 50-g glucose screening test in patients who had a negative 100-g oral glucose tolerance test remains controversial. We investigated the impact of the 50-g glucose screening test results on neonatal outcome in pregnant women with uncomplicated pregnancies, who had no risk factors according to ACOG criteria.
Patients And Methods: Three hundred eighty-six pregnant women with singleton pregnancies were prospectively screened with 50-g glucose challenge test between 24 and 28 weeks. If the test result was >140 mg/dl, a 100-g 3-hour oral glucose tolerance test was performed. Patients with a positive screening test, but not diagnosed as gestational diabetes mellitus constituted the study group, and patients with a negative screening test constituted the control group. Cesarean rates, neonatal birth weights and complications were compared between these groups.
Results: The cesarean delivery rates were not statistically different between the study and control groups (8.3% vs. 6.4%, P>0.05). The rates of macrosomic births were 10.0% in the study group, and 6.4% in the control group (P>0.05), but the mean birth weight (3451.67 +/- 355.70 g) in the study group was significantly higher than the mean birth weight (3296.29 +/- 365.14 g) in the control group (P=0.003). Neonatal hypoglycemia and hyperbilirubinemia was also encountered more often in babies of pregnant women with a positive 50-g glucose challenge test but negative 100-g glucose tolerance test.
Conclusion: Because of similarities with gestational diabetes mellitus on the basis of perinatal outcomes, the non-diabetic pregnant women with 50-g glucose screen test result over 140 mg/dl but a negative 100-g OGTT should be followed closely.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148120 | PMC |
http://dx.doi.org/10.5144/0256-4947.2004.280 | DOI Listing |
BJOG
January 2025
Women's, Children's and Adolescents' Health Program, Burnet Institute, Melbourne, Australia.
Background: Evidence suggests L-arginine may be effective at reducing pre-eclampsia and related outcomes. However, whether L-arginine can prevent or only treat pre-eclampsia, and thus the target population and timing of initiation, remains unknown.
Objectives: To evaluate the effects of L-arginine and L-citrulline (precursor of L-arginine) on the prevention and treatment of pre-eclampsia.
Diabetes Metab Res Rev
January 2025
Faculty of Health and Medical Sciences, Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
Aim: To synthesise the evidence from clinical trials and observational studies using omics techniques to investigate the impact of diet and lifestyle factors on metabolite profile in pregnancy, and in the prevention and management of gestational diabetes mellitus (GDM).
Materials And Methods: A systematic literature search was performed using PubMed, Ovid, CINAHL, and Web of Science databases in October 2023 and updated in September 2024. Inclusion criteria were randomised controlled trials (RCT) or non-RCTs in pregnant women with or without GDM, that measured diet and lifestyle factors, and which applied post-transcriptional omics approaches.
BMJ Open
January 2025
Department of Health Policy Planning and Management, Makerere University School of Public Health, Kampala, Uganda
Objectives: Empowering communities through identifying and unlocking community capacities and capabilities is vital for improving community health systems. This study assessed the community health system's status quo and readiness for implementing a government-led, partner-supported community health worker project.
Design: A mixed methods cross-sectional study.
Environ Res
January 2025
School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; National Institute of Science and Technology for Detection, Toxicological Evaluation and Removal of Micropollutants and Radioactive Substances (INCT-DATREM). Electronic address:
Diisopentyl phthalate (DiPP) is present in many consumer goods, but can be absorbed into the human body, and can disrupt the endocrine system affecting reproductive health and fetal development. Studies revealed that biological samples of pregnant women in Brazil contained DiPP, raising even more the concerns about its usage. This study investigated how DiPP concentrations (12.
View Article and Find Full Text PDFInfect Dis Now
January 2025
Department of Medical Microbiology and Virology. NHS Grampian, Aberdeen, UK. Electronic address:
Context: Recent advances in the development of rapid SARS-CoV-2 point of care (POC) testing provided an opportunity to aid clinical decision making in front-line healthcare settings. Perspectives of POC COVID-19 screening of pregnant women are under-researched.
Objective: To assess the impact of a SARS-CoV-2 POC testing platform implemented in a busy maternity hospital, with limited isolation capacity, during the third wave of the COVID-19 pandemic.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!